american
colleg
rheumatolog
european
leagu
rheumat
continu
updat
guidelin
recommend
rheumatoid
arthriti
ra
treatment
last
two
decad
due
constant
develop
new
antirheumat
drug
among
dna
select
autoantigen
peptidebas
vaccin
promis
new
therapeut
strategi
ra
treatment
recent
develop
rheumavax
base
autolog
dendrit
cell
modifi
nuclear
factor
inhibitor
expos
four
citrullin
peptid
antigen
complet
safeti
trial
promis
result
singlecent
openlabel
firstinhuman
phase
trial
addit
sever
dna
vaccin
base
anticytokin
chicken
type
ii
collagen
ccii
target
costimulatori
signal
pathway
complet
preclin
trial
comparison
advantag
dna
vaccin
treatment
ra
obviou
fascin
first
compar
immunosuppress
synthet
biolog
diseasemodifi
antirheumat
drug
dmard
even
newli
market
oral
janu
kinas
jak
inhibitor
dna
vaccin
induc
gener
immunosuppress
associ
variou
advers
effect
thu
compromis
host
defens
increas
risk
infect
secondli
compar
emerg
antigenspecif
immunotherapi
involv
tolerogen
antigen
peptid
dendrit
cell
dc
regulatori
cell
treg
therapi
small
interf
rna
sirna
base
therapi
etc
dna
vaccin
prepar
larg
quantiti
low
cost
store
long
period
due
good
stabil
lastli
point
fact
antigenspecif
dna
vaccin
show
good
therapeut
efficaci
rel
longterm
durabl
respons
potenti
induc
immun
toler
target
specif
selfantigen
regul
whole
network
immun
system
reestablish
immun
balanc
reason
dna
vaccin
undoubtedli
innov
person
therapeut
strategi
arena
ra
immunotherapi
type
ii
collagen
cii
critic
autoantigen
ra
pathogenesi
nativ
chicken
type
ii
collagen
nccii
shown
effect
treatment
ra
patient
howev
purifi
nccii
caus
structur
degener
loss
biolog
function
also
contamin
pathogen
virus
base
valuabl
find
previous
develop
therapeut
vaccin
encod
ccii
found
efficaci
compar
current
gold
standard
drug
methotrex
mtx
rat
model
collageninduc
arthriti
cia
recent
show
safe
welltoler
therapeut
vaccin
markedli
affect
balanc
humor
cellular
immun
respons
immunogen
normal
rat
administ
intramuscular
inject
integr
research
evid
studi
strongli
suggest
promis
therapeut
dna
vaccin
howev
point
dna
vaccin
inject
intramuscularli
target
dna
deliveri
present
studi
actual
far
variou
vehicl
technolog
dna
deliveri
use
preclin
clinic
trial
viral
vector
earliest
use
carrier
deliv
protect
dna
use
gene
therapi
restrict
due
risk
trigger
sever
immun
respons
insert
genom
consequ
nonvir
dna
deliveri
system
physic
method
chemic
vector
also
develop
transfer
dna
cell
physic
method
use
carrier
reli
physic
forc
enhanc
cell
membran
permeabl
facilit
gene
cell
includ
needl
microneedl
jet
inject
electropor
gene
gun
ultrasound
hydrodynam
inject
chemic
vector
prepar
carrier
chemic
method
carri
dna
nucleu
electrostat
attract
anion
dna
cation
lipid
polym
dna
encapsul
use
variou
biodegrad
polym
prepar
micrometr
nanometr
spheric
structur
contain
dna
variou
advanc
prepar
technolog
biolog
transfect
mediat
exampl
protein
transduct
domain
ptd
name
cell
penetr
peptid
exosom
etc
technolog
support
develop
prepar
formul
clinic
applic
dna
vaccin
near
futur
new
therapeut
dna
vaccin
high
druggabl
whether
exogen
gene
quickli
remov
unintegr
host
genom
take
effect
vivo
import
scientif
issu
also
relat
whether
new
vaccin
approv
formal
appli
clinic
practic
accord
vaccin
regul
fda
cfda
studi
pharmacokinet
new
develop
dna
vaccin
must
carri
clinic
trial
applic
includ
evalu
dynam
profil
persist
biodistribut
integr
risk
etc
end
present
studi
evalu
dynam
profil
blood
biodistribut
mrna
ccii
protein
investig
whether
plasmid
integr
occur
variou
tissu
vaccin
normal
rodent
first
time
investig
pharmacokinet
dna
vaccin
gene
protein
level
reveal
pharmacokinet
genom
integr
risk
help
futur
clinic
trial
applic
recent
report
vaccin
dose
mgkg
welltoler
rat
optim
therapeut
dose
induc
product
anticii
igg
alter
express
level
cytokin
tlymphocyt
subset
normal
rat
suggest
promis
therapeut
dna
vaccin
high
druggabl
therefor
evalu
dynam
profil
rat
dose
assess
clearanc
vaccin
analyz
persist
peripher
blood
vaccin
normal
rat
singl
intramuscular
inject
measur
mrna
level
six
rat
three
sex
rtqpcr
h
day
vaccin
copi
plasmid
dna
detect
h
postinject
fig
h
plasmid
dna
still
present
blood
anim
although
plasmid
copi
number
pcn
reduc
compar
time
point
rapid
clearanc
blood
subsequ
observ
day
postinject
plasmid
almost
undetect
except
anim
show
neglig
express
mean
rna
valu
day
day
lower
limit
quantit
lloq
limit
detect
lod
valu
time
point
lod
addit
signal
detect
vaccin
h
next
investig
biodistribut
variou
tissu
vaccin
normal
rat
singl
intramuscular
inject
mrna
express
assess
rtqpcr
day
vaccin
respect
day
transcript
detect
muscl
inject
site
anim
disappear
thereaft
day
mrna
detect
heart
liver
lung
kidney
spleen
thymu
howev
day
transcript
present
lung
tissu
product
lloq
detect
day
day
vaccin
tissu
fig
addit
mrna
detect
peripher
blood
day
vaccin
data
shown
consist
result
obtain
continu
harvest
blood
sampl
transcript
detect
time
point
male
femal
gonad
data
shown
expect
signal
lod
normal
salin
ns
treat
neg
control
reaction
sentinel
sampl
indic
crosscontamin
occur
pcr
analysi
establish
dynam
profil
ccii
protein
vaccin
normal
rat
carri
vivo
bioluminesc
imag
bli
intramuscular
inject
luciferaseconjug
almost
bioluminesc
back
abdomen
rat
h
day
post
inject
three
repeat
independ
experi
fig
consid
dosag
may
low
gener
protein
higher
dosag
mgkg
dna
vaccin
inject
intramuscularli
rat
includ
one
shave
likewis
still
observ
bli
signal
appear
data
shown
given
weak
signal
due
thick
fur
also
investig
dynam
profil
ccii
protein
balbc
mice
inject
intramuscularli
intraven
vaccin
signal
intens
significantli
higher
mice
rat
compar
dose
fig
show
result
biodistribut
persist
ccii
protein
three
vaccin
male
mice
inject
via
intramuscular
rout
bli
signal
appear
inject
left
hind
thigh
site
start
h
postinject
day
result
three
femal
mice
display
almost
bioluminesc
observ
inject
left
hind
thigh
site
except
abdomin
imag
day
postinject
fig
show
dorsal
imag
result
ccii
protein
three
vaccin
femal
mice
h
day
signal
appear
inject
tail
site
h
day
abdomin
imag
three
vaccin
male
mice
h
h
signal
may
appear
liver
inject
via
intraven
rout
signal
tail
inject
site
weaker
appear
male
mous
day
signal
may
liver
never
observ
femal
mice
independ
experi
bli
valu
day
fig
one
mous
show
continu
express
ccii
protein
inject
muscl
tail
site
respect
bli
signal
intens
vari
fold
short
ccii
protein
disappear
day
vaccin
via
intramuscular
intraven
rout
mice
result
indic
vivo
imag
use
combin
luciferas
gene
profil
rel
biodistribut
persist
ccii
protein
host
assess
risk
integr
gene
host
genom
perform
rtqpcr
analysi
day
blood
variou
tissu
sampl
normal
rat
intramuscularli
inject
singl
dose
ns
intern
control
gene
detect
dna
prepar
detect
blood
sampl
nsinject
rat
dna
lod
tabl
moreov
detect
major
vaccin
normal
rat
pcn
extrem
low
lod
posit
sampl
importantli
testi
ovari
sampl
rat
neg
gene
result
indic
gene
integr
genom
dna
vaccin
rat
therapeut
dna
vaccin
consider
advantag
tradit
dmard
biolog
agent
tofacitinib
glucocorticoid
sinc
capabl
induc
cellular
humor
immun
respons
also
modul
immun
system
fact
critic
aspect
therapeut
dna
vaccin
induct
immun
toler
especi
import
treatment
refractori
autoimmun
diseas
ra
multipl
sclerosi
insulindepend
diabet
mellitu
involv
dysfunct
innat
adapt
immun
system
howev
alway
concern
regard
safeti
therapeut
dna
vaccin
due
lack
longterm
safeti
data
human
result
preclin
assess
indic
transcript
protein
express
rapidli
clear
inject
normal
rat
gene
integr
host
genom
provid
evid
safeti
vaccin
studi
monitor
biodistribut
mrna
rat
administ
singl
inject
found
transcript
level
peripher
blood
peak
h
postimmun
rapidli
decreas
undetect
day
analysi
variou
tissu
reveal
transcript
present
inject
muscl
day
postimmun
time
detect
heart
liver
lung
kidney
spleen
thymu
day
express
restrict
lung
importantli
transcript
present
reproduct
organ
time
point
result
confirm
rapid
clearanc
underscor
safeti
advantag
vaccin
deriv
pathogen
microorgan
may
persist
express
exogen
gene
host
result
mostli
consist
data
anim
speci
demonstr
plasmid
dna
introduc
inject
electropor
clear
within
sever
minut
hour
day
peak
time
maximum
plasmid
dna
concentr
inject
site
show
similar
variabl
previou
studi
biodistribut
nake
plasmid
dna
encod
fibroblast
growth
factor
type
limit
inject
site
plasma
serum
neg
major
treat
patient
differ
result
obtain
use
vascular
endotheli
growth
factora
vaccin
therapeut
vaccin
use
discrep
like
due
target
differ
gene
use
differ
express
vector
although
studi
human
anim
structur
gene
target
biodistribut
persist
dna
vaccin
influenc
type
express
vector
use
high
vs
low
express
well
rout
administr
eg
intramuscular
intravascular
tail
vein
inject
particl
bombard
vivo
electropor
howev
exist
research
focus
exogen
gene
pathogen
microorgan
human
immunodefici
viru
hepat
c
viru
malaria
measl
ebola
rather
human
anim
studi
use
express
vector
highli
stabl
high
copi
number
therefor
wide
use
transient
gene
express
conveni
futur
clinic
applic
chose
deliv
vaccin
intramuscular
inject
although
rout
administr
theori
increas
transfect
effici
persist
plasmid
dna
target
tissu
may
affect
could
increas
risk
integr
host
genom
also
possibl
dynam
profil
biodistribut
dna
vaccin
depend
target
gene
express
vector
use
although
remain
confirm
detail
analys
molecular
imag
report
gene
use
noninvas
monitor
exogen
endogen
target
gene
express
intracellular
biolog
event
present
studi
use
approach
investig
therapeut
action
vivo
evalu
distribut
ccii
protein
real
time
use
luciferas
report
track
express
ccii
protein
condit
atp
oxygen
substrat
luciferin
oxid
express
luciferas
result
bioluminesc
enabl
quantit
local
fuse
gene
product
avoid
background
fluoresc
fur
food
gastrointestin
tract
thu
bli
use
detect
express
protein
high
sensit
although
intens
signal
weaker
fluoresc
molecul
reason
difficult
detect
signal
vaccin
wistar
rat
live
imag
experi
vaccin
mice
consider
interindividu
variabl
exampl
everi
mous
bli
signal
given
time
point
moreov
differ
signal
observ
two
sex
dorsal
abdomin
posit
signal
acquisit
besid
inher
factor
inject
speed
site
may
contribut
variabl
therefor
present
rel
consist
result
mice
plasmid
dna
vector
potenti
incorpor
host
genom
via
random
integr
homolog
recombin
retrovir
mechan
increas
probabl
chromosom
insert
mutat
genom
instabl
dysregul
cell
growth
disruptioninactiv
tumor
suppressor
gene
oncogenesi
integr
exogen
dna
germ
cell
induc
genet
defect
offspr
although
random
integr
plasmid
dna
host
genom
follow
intramuscular
deliveri
electropor
report
probabl
event
consid
extrem
low
nonetheless
investig
potenti
genom
integr
found
transcript
detect
analyz
tissu
detect
limit
approxim
dna
indic
risk
integr
plasmid
dna
vaccin
deliv
intramuscular
inject
neglig
mammalian
genom
thought
mechan
identifi
degrad
foreign
nucleotid
sequenc
observ
support
possibl
worth
note
tissu
posit
transcript
found
neg
analysi
plasmid
dna
integr
therefor
conclud
plasmid
dna
remain
extrachromosom
rapidli
degrad
therefor
pose
littl
risk
germlin
transmiss
far
sever
consensu
mechan
plasmid
dna
vaccin
includ
clear
vaccin
anim
human
bodi
though
experi
present
studi
first
mechan
extracellular
blood
plasmid
dna
quickli
degrad
enzym
nucleas
second
mechan
antigenexpress
cell
muscl
clear
immun
system
cell
third
mechan
plasmid
dna
vaccin
degrad
cytoplasm
releas
exocytosi
fourth
mechan
plasmid
dna
vaccin
intravascular
deliveri
quickli
degrad
liver
addit
plasmid
dna
vaccin
gene
gun
bombard
skin
quickli
clear
due
normal
slough
epidermi
summari
rapidli
clear
tissu
rat
within
week
intramuscular
administr
dose
importantli
exogen
gene
integr
host
genom
result
strongli
support
clinic
develop
therapeut
vaccin
ra
treatment
vaccin
gener
eukaryot
express
vector
previous
construct
laboratori
genbank
databas
access
no
contain
fulllength
cdna
encod
ccii
delet
npropeptid
signal
peptid
sequenc
kozak
consensu
sequenc
result
recombin
plasmid
produc
escherichia
coli
purifi
use
endofre
megaprep
kit
qiagen
valencia
ca
usa
luciferas
label
vaccin
construct
restrict
enzym
hindiii
protect
base
contain
kozak
consensu
sequenc
flexibl
peptid
sequenc
gene
respect
luciferas
gene
link
flexibl
peptid
sequenc
inbr
femalemal
wistar
rat
week
old
balbc
mice
week
old
obtain
anim
breed
center
academi
militari
medic
scienc
beij
china
maintain
specif
pathogenfre
condit
experi
perform
accord
guidelin
academi
militari
medic
scienc
anim
welfar
committe
total
normal
rat
use
studi
includ
male
femal
receiv
singl
intramuscular
inject
left
hind
limb
musculi
bicep
femori
six
rat
per
time
point
three
sex
sacrif
differ
time
point
vaccin
rat
anesthet
ether
variou
tissu
harvest
analysi
tissu
distribut
dna
integr
remain
six
rat
inject
normal
salin
ns
neg
control
evalu
persist
six
rat
three
sex
intramuscularli
inject
left
hind
limb
musculi
bicep
femori
singl
dose
blood
sampl
collect
orbit
venou
plexu
differ
time
point
postvaccin
rna
extract
sampl
blood
tissu
includ
heart
liver
spleen
lung
kidney
thymu
muscl
inject
site
ovari
testi
obtain
variou
time
point
total
rna
extract
use
trizol
reagent
life
technolog
carlsbad
ca
usa
accord
manufactur
protocol
rna
extract
chloroform
precipit
isopropyl
alcohol
dissolv
diethyl
pyrocarbonatetr
water
revers
transcrib
reaction
volum
use
revers
transcript
reagent
life
technolog
min
follow
min
min
incub
ice
rtqpcr
carri
use
platinum
taq
dna
polymeras
life
technolog
reversetranscrib
product
templat
taqman
probe
detect
reagent
result
cdna
amplifi
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
follow
cycl
condit
min
cycl
rat
use
intern
control
amplifi
fragment
size
primer
probe
sequenc
shown
tabl
rna
sampl
isol
differ
tissu
analyz
parallel
neg
control
sampl
rat
inject
ns
reaction
sentinel
control
sampl
use
templat
posit
control
consist
combin
cdna
blood
variou
tissu
rat
treat
ns
use
templat
set
pcr
reaction
dna
standard
refer
gene
serial
dilut
blood
tissu
extract
vehicletr
rat
run
parallel
quantifi
rang
plasmid
copi
number
pcn
lod
lloq
per
reaction
pcn
respect
rna
accept
criteria
run
includ
standard
curv
correl
coeffici
well
pcn
valu
lod
reagent
control
reaction
lack
templat
extract
neg
control
reaction
use
nsvehicletr
rat
cdna
specimen
accept
criteria
includ
threshold
cycl
ct
ie
cycl
detect
report
signal
baselin
fluoresc
differ
sampl
duplic
sampl
lloq
quantifi
plasmid
transcript
level
standard
curv
gener
plot
mean
ct
valu
standard
logn
start
copi
number
obtain
rtqpcr
sampl
valu
fit
curv
linear
regress
analysi
arithmet
mean
copi
number
three
duplic
reaction
calcul
data
express
pcn
per
rna
six
wistar
rat
balbc
mice
three
sex
administ
luciferas
genelabel
via
singl
intramuscular
inject
dose
respect
anoth
six
balbc
mice
three
sex
inject
intraven
imag
immun
ratsmic
intraperiton
inject
singl
dose
mgkg
dluciferin
substrat
ns
anim
scan
h
day
immun
vv
anesthesia
bli
perform
use
dedic
small
anim
ivi
spectrum
live
imag
system
perkinelm
waltham
usa
min
postluciferin
administr
data
analyz
use
live
imag
softwar
perkinelm
bioluminesc
signal
record
averag
radianc
unit
blood
tissu
sampl
includ
heart
liver
spleen
lung
kidney
thymu
muscl
inject
site
ovari
testi
analyz
evalu
extent
integr
host
genom
briefli
genom
dna
extract
use
qiaamp
dna
mini
kit
qiagen
hilden
germani
puriti
determin
assur
absorpt
ratio
nm
isol
genom
dna
analyz
presenc
housekeep
gene
exogen
gene
sequenc
rtqpcr
briefli
ng
purifi
genom
dna
templat
amplifi
use
platinum
taq
dna
polymeras
taqman
probe
well
sens
antisens
primer
target
fragment
gene
rat
gene
amplifi
intern
control
tabl
genom
dna
spike
use
posit
control
purifi
genom
dna
nsinject
rat
use
templat
neg
control
reaction
amplif
condit
describ
section
rtqpcr
analysi
mrna
biodistribut
dna
standard
run
parallel
plate
quantifi
rang
pcn
pcn
lod
lloq
reaction
pcn
respect
ie
dna
arithmet
mean
copi
number
duplic
reaction
gene
fragment
sampl
calcul
data
shown
describ
section
rtqpcr
analysi
mrna
biodistribut
repres
amplif
plot
linear
standard
curv
gene
shown
fig
b
respect
data
deriv
rtqpcr
present
mean
sd
analyz
student
test
use
spss
softwar
spss
inc
chicago
il
usa
p
consid
statist
signific
